Dr. Lehmann’s research is driven by the urgent need to address the global crisis of antibiotic resistance. Since the discovery of antibiotics in the early to mid-20th century, bacteria have rapidly evolved mechanisms to resist their effects. As a result, many antibiotics once considered groundbreaking have lost their efficacy, and even the most advanced broad-spectrum agents are now failing in the face of widespread resistance. The current cycle—introducing new drugs only to see resistant strains emerge—has led to a troubling rise in infections and deaths caused by drug-resistant pathogens.

Dr. Lehmann’s work focuses on an alternative strategy informed by a growing understanding of the human microbiome. Long before antibiotics were used, the beneficial bacteria within the microbiome played a critical role in maintaining health by competing with and suppressing harmful microbes. However, antibiotic use often disrupts this balance, killing protective bacteria and allowing drug-resistant pathogens to thrive.

In response, Dr. Lehmann is developing approaches to restore and protect the beneficial components of the microbiome. By promoting the health and resilience of the microbiome, this research aims to prevent infections, reduce reliance on traditional antibiotics, and provide a powerful new avenue in the fight against antibiotic-resistant disease.